屈肌腱切断术在糖尿病足减压治疗中的前瞻性随机对照研究

注册号:

Registration number:

ChiCTR2600126071 

最近更新日期:

Date of Last Refreshed on:

2026-06-03 11:34:41 

注册时间:

Date of Registration:

2026-06-03 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

屈肌腱切断术在糖尿病足减压治疗中的前瞻性随机对照研究

Public title:

A prospective randomized controlled study of flexor tenotomy for offloading treatment of diabetic foot

注册题目简写:

English Acronym:

研究课题的正式科学名称:

屈肌腱切断术在糖尿病足减压治疗中的前瞻性随机对照研究

Scientific title:

A prospective randomized controlled study of flexor tenotomy for offloading treatment of diabetic foot

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张妲 

研究负责人:

张妲 

Applicant:

Da Zhang 

Study leader:

Da Zhang 

申请注册联系人电话:

Applicant telephone:

+86 134 8866 8972

研究负责人电话:

Study leader's
telephone:

+86 134 8866 8972

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zhangda79@aliyun.com

研究负责人电子邮件:

Study leader's E-mail:

zhangda79@aliyun.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市海淀区阜成路30号

研究负责人通讯地址:

北京市海淀区阜成路30号

Applicant address:

No. 30, Fucheng Road, Haidian District, Beijing

Study leader's address:

No. 30, Fucheng Road, Haidian District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国人民解放军空军特色医学中心

Applicant's institution:

Air Force Medical Center, PLA

研究负责人所在单位:

中国人民解放军空军特色医学中心

Affiliation of the Leader:

Air Force Medical Center, PLA

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

空特(科研)第2026-04-PJ01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国人民解放军空军特色医学中心伦理委员会

Name of the ethic committee:

Ethics Committee of Air Force Medical Center

伦理委员会批准日期:

Date of approved by ethic committee:

2026-05-20 00:00:00

伦理委员会联系人:

王威

Contact Name of the ethic committee:

Wei Wang

伦理委员会联系地址:

北京市海淀区阜成路30号

Contact Address of the ethic committee:

No. 30, Fucheng Road, Haidian District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 6692 8575

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国人民解放军空军特色医学中心

Primary sponsor:

Air Force Medical Center, PLA

研究实施负责(组长)单位地址:

北京市海淀区阜成路30号

Primary sponsor's address:

No. 30, Fucheng Road, Haidian District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

空军特色医学中心

具体地址:

北京市海淀区阜成路30号

Institution
hospital:

Air Force Medical Center

Address:

No. 30, Fucheng Road, Haidian District, Beijing

经费或物资来源:

空军军医大学

Source(s) of funding:

Air Force Military Medical University

研究疾病:

糖尿病性足溃疡  

Target disease:

diabetic foot ulcer

研究疾病代码:

Target disease code:

研究类型:

治疗研究

Study type:

Treatment study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究旨在通过前瞻性、随机、对照设计,评估屈肌腱切断术对比常规保守治疗,对糖尿病足溃疡伴前足高压患者的减压疗效与安全性。主要目的是明确该手术能否有效促进溃疡愈合、降低复发率,并为糖尿病足规范化治疗提供高级别临床证据。  

Objectives of Study:

This study aims to evaluate the decompression efficacy and safety of flexor tenotomy compared with conventional conservative treatment in patients with diabetic foot ulcers and forefoot high pressure through a prospective, randomized, controlled design. The primary objective is to determine whether this surgical procedure can effectively promote ulcer healing and reduce the recurrence rate, thereby providing high-level clinical evidence for the standardized treatment of diabetic foot.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

足部感染需外科清创或截肢者;有严重下肢血管闭塞(ABI<0.7)或需血运重建者;合并严重心脑血管疾病、肝肾功能衰竭等不适宜手术者;凝血功能障碍或抗凝治疗者;妊娠期、哺乳期妇女;精神障碍或依从性差者。

Exclusion criteria:

Patients with foot infection requiring surgical debridement or amputation; those with severe lower limb arterial occlusion (ABI < 0.7) or requiring revascularization; those with serious cardiovascular or cerebrovascular diseases, liver or kidney failure, or other conditions making them unsuitable for surgery; those with coagulation disorders or on anticoagulant therapy; pregnant or lactating women; those with mental disorders or poor compliance.

研究实施时间:

Study execute time:

From 2026-06-03 00:00:00 To 2028-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-06-03 00:00:00 To 2028-12-31 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

63

Group:

experimental group

Sample size:

干预措施:

选择性趾屈肌腱切断术

干预措施代码:

Intervention:

selective toe flexor tenotomy

Intervention code:

组别:

对照组

样本量:

63

Group:

Control group

Sample size:

干预措施:

给予常规糖尿病足治疗方案,包括:血糖控制、抗感染、改善循环等基础治疗;足底溃疡标准伤口管理;保护性鞋垫或定制减压鞋使用;医学教育及生活方式干预。

干预措施代码:

Intervention:

Standard treatment protocol for diabetic foot, including: basic treatments such as glycemic control, anti-infection, and improvement of circulation; standard wound management for plantar ulcers; use of protective insoles or custom-made offloading shoes; medical education and lifestyle intervention.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

中国人民解放军空军特色医学中心 

单位级别:

三甲 

Institution
hospital:

Air Force Medical Center, PLA

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

溃疡复发率

指标类型:

主要指标

Outcome:

ulcer recurrence rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

足底压力分布变化

指标类型:

次要指标

Outcome:

changes in plantar pressure distribution

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

足部溃疡完全愈合率

指标类型:

次要指标

Outcome:

rate of complete healing of foot ulcers

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

创面愈合时间

指标类型:

次要指标

Outcome:

wound healing time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后并发症发生率

指标类型:

次要指标

Outcome:

postoperative complication rate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

足趾活动度与结构变化

指标类型:

次要指标

Outcome:

toe range of motion and structural changes

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疼痛评分

指标类型:

次要指标

Outcome:

pain score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活质量评估

指标类型:

次要指标

Outcome:

quality of life assessment

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

no

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

经筛选符合条件的受试者,研究负责人张妲将以随机数字表法分配到以下两组中的一组:屈肌腱切断术组:接受屈肌腱切断术联合常规保守治疗;常规保守治疗组:仅接受常规保守治疗。

Randomization Procedure (please state who generates the random number sequence and by what method):

Eligible subjects who meet the screening criteria will be assigned by the study principal investigator, Da Zhang, to one of the following two groups using a random number table method: the flexor tenotomy group, receiving flexor tenotomy combined with conventional conservative treatment; or the conventional conservative treatment group, receiving conventional conservative treatment alone.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

由于本研究为手术干预性随机对照研究,试验组接受屈肌腱切断术减压治疗,对照组接受常规/标准治疗,因此受试者及实施治疗的临床医生无法实施盲法。本研究采用开放标签设计。但为尽量减少偏倚,结局评估人员及统计分析人员对分组信息实行盲法。创面愈合情况、复发情况及其他结局指标的评估尽可能由不知晓分组的研究人员完成,统计分析阶段使用编码数据,在数据库锁定前不公开分组信息。

Blinding:

Because this is a surgical randomized controlled trial, participants in the intervention group will receive flexor tenotomy for off-loading treatment, while those in the control group will receive conventional/standard treatment; therefore, blinding of participants and treating clinicians is not feasible. This study is designed as an open-label trial. However, to minimize bias, outcome assessors and statisticians will be blinded to group allocation whenever feasible. Wound healing, recurrence, and other study outcomes will be assessed, as far as possible, by investigators unaware of treatment allocation, and coded data will be used for statistical analysis until database lock.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究采用标准化病例报告表(Case Report Form,CRF)进行数据采集和管理。所有研究数据由经过培训的研究人员按照统一要求填写CRF表,并由研究团队定期进行数据核查与质量控制,以确保数据的准确性、完整性和一致性。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Standardized case report forms (CRFs) will be used for data collection and management. All study data will be recorded by trained research staff according to standardized procedures, and regular data verification and quality control will be performed to ensure the accuracy, completeness, and consistency of the data.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-06-03 11:34:07